MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells

Table 1 Clinical characteristics of the DLBCL patients and univariate analysis for predictors of PFS and OS in the training and validation cohort

Characteristics	Training cohort (n = 60)	Validation cohort (n = 140)	P value	Training cohort		Validation cohort
Characteristics	Training cohort (n = 60)	Validation cohort (n = 140)	P value	P value for PFS	P value for OS	P value for PFS	P value for OS
Age
> 60 years	26/60 (43.3%)	49/140 (35.0%)	0.265	0.026	0.045	0.075	0.028
≤60 years	34/60 (56.7%)	91/140 (65.0%)
Sex
Female	24/60 (40.0%)	56/140 (40.0%)	1.000	0.261	0.541	0.396	0.918
Male	36/60 (60.0%)	84/140 (60.0%)
Performance status (ECOG)
0–1	51/60 (85.0%)	119/140 (85.0%)	1.000	0.100	0.048	< 0.001	0.210
2	9/60 (15.0%)	23/140 (15.0%)
Lactic dehydrogenase
Normal	37/60 (61.7%)	81/140 (57.9%)	0.616	0.045	0.113	< 0.001	0.011
Elevated	23/60 (38.3%)	59/140 (42.1%)
Ann Arbor stage
I-II	25/60 (41.7%)	72/140 (51.4%)	0.206	0.003	0.010	0.020	0.081
III-IV	35/60 (58.3%)	68/140 (48.6%)
Extranodal involvement
Yes	20/60 (33.3%)	33/140 (23.6%)	0.165	< 0.001	< 0.001	0.988	0.918
No	40/60 (66.7%)	107/140 (76.4%)
Revised International Prognostic Index (R-IPI)
Very good	10/60 (16.7%)	39/140 (27.9%)	0.230	< 0.001	0.001	0.013	0.323
Good	31/60 (51.7%)	60/140 (42.9%)
Poor	19/60 (31.7%)	41/140 (29.3%)
MiR155
Low	31/60 (51.7%)	69/140 (49.3%)	0.758	0.012	0.015	0.022	0.021
High	29/60 (48.3%)	71/140 (50.7%)

ISSN: 1476-4598